Talk:David Zarling

This article was previously nominated for deletion. The result of the discussion was Consensus to keep.

This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.

If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page.

Biography: Science and Academia

	Biography portal This article is within the scope of WikiProject Biography, a collaborative effort to create, develop and organize Wikipedia's articles about people. All interested editors are invited to join the project and contribute to the discussion. For instructions on how to use this banner, please refer to the documentation.BiographyWikipedia:WikiProject BiographyTemplate:WikiProject Biographybiography articles
	This article is supported by the science and academia work group.

United States: Dartmouth Low‑importance

	United States portal This article is within the scope of WikiProject United States, a collaborative effort to improve the coverage of topics relating to the United States of America on Wikipedia. If you would like to participate, please visit the project page, where you can join the ongoing discussions. Template Usage Articles Requested! Become a Member Project Talk Alerts United StatesWikipedia:WikiProject United StatesTemplate:WikiProject United StatesUnited States articles
Low	This article has been rated as Low-importance on the project's importance scale.
	This article is supported by WikiProject New Hampshire - Dartmouth College (assessed as Low-importance).

Untitled

- I attended David Zarling's presentation at 5th annual cancer drugs R&D conference in Phoenix, Arizona (Feb 21-22). His new company has developed a set of drugs that hypothetically can help with even the latest stages of prostate cancer when it gets to the bone (6 months prognosis).

- I know about the diseases not only from textbooks and follow clinical trials of Synta and Cougar. Colby's drug candidates will probably have lower toxicity and higher efficacy then Synta's and Cougar's. I would like to enroll into early stage clinical prevention trials...

- I asked him for information on Colby, his scientists and himself, but since the company is in early stage, most of the data is confidential. He sent me his biography and I thought it would be worthwhile to put his profile onto Wikipedia.

- I work for GTCbio and volunteer at several institutions targeting diseases of aging. This article is not self promotion and any help with getting the message that Colby developed really potent prostate cancer therapeutics is much appreciated. There are many men that need hope.